Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/66—Microorganisms or materials therefrom
  • A61K35/76—Viruses; Subviral particles; Bacteriophages
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2795/00—Bacteriophages
  • C12N2795/00011—Details
  • C12N2795/00021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2795/00—Bacteriophages
  • C12N2795/00011—Details
  • C12N2795/00032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to the medical field of the treatment of bacterial infections, especially on the basis of bacteriophage therapy.
• the present invention relates to a bacteriophage which is capable of infecting a variety of bacteria. Furthermore, the present invention relates to a composition containing a therapeutically effective amount of a bacteriophage according to the present invention.
• the bacteriophage and/or the composition according to the present invention are suitable for the use in the treatment of bacterial infections, and other infections.
• a bacterial infection is a proliferation or growth of a harmful strain or multiple harmful strains of bacteria on or inside the body and can be caused by various pathogenic species of bacteria.
• the most common bacteria causing healthcare-associated infections belong to the genera or families of Acinetobacter, Bacteroides, Burkholderia, Clostridium, Enterobacteriaceae, Enterococcus, Escherichia, Klebsiella, Staphylococcus, Streptococcus, Mycobacterium and Pseudomonas.
• Bacterial infections can occur in any area of the body and are linked with various clinical pictures or symptoms and lead to different illnesses.
• Common clinical pictures or illnesses caused by bacteria are infections of the respiratory tract (for example pneumonia or bronchitis), wound infections, septicemia, meningitis, ear, nose and throat infections (for example otitis media or tonsillitis), infections of bones and joints (for example arthritis, osteomyelitis or osteitis).
• infections of the respiratory tract for example pneumonia or bronchitis
• wound infections for example septicemia, meningitis, ear, nose and throat infections (for example otitis media or tonsillitis), infections of bones and joints (for example arthritis, osteomyelitis or osteitis).
• antibiotics are usually treated with antibiotics.
• An antibiotic is a type of antimicrobial substance which is active against bacteria.
• the main classes of antibiotics are ⁇ -lactam antibiotics, glycopeptide antibiotics, quinolone antibiotics, polyketide antibiotics, aminoglycoside antibiotics, polypeptide antibiotics and/or sulfonamide antibiotics.
• the antibiotic either kills or inhibits the growth of bacteria, depending on the individual mechanism of action.
• the mode of action of antibiotics is rather unspecific, i.e. antibiotics not only target specifically the pathogenic bacteria but also useful bacteria, like the intestinal flora. Due to their low specificity, therapies with antibiotics often go along with several undesired side effects, especially diarrhea and allergic reactions.
• ESKAPE organisms Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa and Enterobacter spp.
• antibiotics especially penicillin, vancomycin and carbapenems.
• Such resistances in particular multiple resistances, make the treatment of infections extremely challenging.
• antibiotic treatment of infections caused by multi-drug resistant bacteria is often ineffective and the growing resistance of pathogenic bacteria is of great importance in medical practice.
• Bacteriophages are viruses that attack or infect bacteria, multiply within the infected bacteria and finally cause disruption of the bacterial cell (lysis).
• the infection and lytic action of bacteriophages is highly specific.
• bacteriophages are mostly specific for the host organism.
• Bacteriophage therapy was described for the first time in 1921 by BRUYNOGHE and MAISIN in the treatment of staphylococcal skin infections. Although the results were promising, little was accomplished in this field during the following years. The idea of potential applications of bacteriophage therapy was abandoned after the introduction of sulphonamides and then antibiotics into medical practice.
• bacteriophage therapy is not well established yet and there exist only a few trial studies with respect to the therapeutic efficacy. Furthermore, many bacteriophages are extremely specific and comprise lytic activity against one or very few strains only. Such high specificity complicates the use of phages in the treatment of bacterial infections in particular with respect to the economic and therapeutic efficiency.
• the problem of the present invention has to be seen in the supply of a new therapeutic concept for the treatment of bacterial infections, particularly infections with antibiotic resistant bacteria.
• the object of the present invention has to be seen in a therapeutic concept for the treatment of bacterial infection, which overcomes the existent problem of effective treatment of infections with antibiotic resistant bacteria and which is further well tolerated and linked with at least reduced side effects in comparison to antibiotics. Furthermore, the new therapeutic concept should be effective against a broad range of bacteria, especially antibiotic resistant bacteria.
• the present invention relates to a bacteriophage as such according to the respective independent claim; furthermore, in particular advantageous embodiments of this aspect are subject-matter the respective dependent claims.
• the present invention relates to a method of treating bacterial infections and/or infection diseases.
• a Caucasian Origin's BP (synonymously Caucasian Origin's Bacteriophage) as deposited at the DSMZ, Inhoffenstr. 7B, 38124 Braunschweig, Germany, under the accession number DSM 33404 has a multifunctional activity against different species of bacteria and is suitable for the use in a highly efficient treatment of bacterial infections and/or infectious diseases caused by various bacteria species.
• subject-matter of the present invention is - according to the first aspect of the present invention - a bacteriophage for the use in the treatment of bacterial infections and/or infectious diseases, wherein the bacteriophage is a Caucasian Origin's Bacteriophage as deposited at Deutsche Stammsammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under the accession no. DSM 33404.
• DSMZ Deutsche Stammsammlung von Mikroorganismen und Zellkulturen GmbH
• the Caucasian Origin's Bacteriophage according to the present invention has a relatively broad efficacy spectrum against particularly for humans pathogenic bacteria and is therefore suitable for the use in the treatment of various bacterial infections on the basis of a bacteriophage therapy. Nevertheless, unlike antibiotics, the bacteriophage does not infect and lyse beneficial bacteria, for example the intestinal flora or the natural skin flora.
• the Caucasian Origin's Bacteriophage according to the present invention belongs to the order of Ligamenvirales and the family of Rudiviridae.
• the phage has been isolated from the waters of the mountainous region of western Georgia.
• the virus is stick or rod-shaped and has a size of about 23 nm in width and 870 nm in length.
• the genome is composed of linear dsDNA.
• the unique capsid protein of the Caucasian Origin's Bacteriophage has an amino acid sequence according to SEQ. ID NO. 3.
• the mRNA sequence coding for the capsid protein is contained in SEQ. ID NO. 4.
• the bacteriophage expresses mRNA sequences according to SEQ. ID NO. 1 and SEQ. ID NO. 2.
• the Caucasian Origin's Bacteriophage has polyvalent properties.
• the host spectrum of the Caucasian Origin's Bacteriophage includes at least the following bacterial strains: Klebsiella pneumoniae, Pseudomonas aeruginosa, Escherichia coli, Enterobacter spp., Acinetobacter baumannii, Salmonella enterica, Proteus vulgaris, Staphylococcus aureus and Streptococcus pyogenes.
• the phage has due to its polyvalent properties a large host spectrum and can infect and lyse a variety of bacterial strains.
• the broad host spectrum makes the Caucasian Origin's Bacteriophage and/or lysates of Caucasian Origin's Bacteriophage suitable for the treatment of a variety of bacterial infections and/or infectious diseases, particularly in humans.
• the bacteriophage and/or the respective lysates can be used as pharmaceutically active component in compositions for the treatment of bacterial infections and/or infectious diseases.
• the host range of the bacteriophage reference is particularly made to the experimental section of this patent application, especially the in vitro studies.
• the bacteriophage according to the present invention in particular in connection with its use in the treatment of bacterial infections, is linked with several advantages, which are delineated hereinafter: Even though most bacteriophages are generally highly specific with respect to their lytic action and host strains, the bacteriophage according to the present invention is characterized by multifunctional or polyvalent activity against different species of bacteria. Particularly, the bacteriophage according to the present invention infects several bacteria strains causing healthcare-associated infections and has lytic activity against Acinetobacter baumannii (carbapenem-resistant), Enterococcus faecium, Pseudomonas aeruginosa (carbapenem-resistant), Enterobacter spp.
• the bacteriophage according to the present invention is - in particular when compared to the unspecific mode of action of antibiotics - suitable for a pathogen-specific therapy for bacterial infections caused by the most common bacteria causing healthcare-associated infections.
• the specificity of the bacteriophage according to the present invention is particularly advantageous as antibiotic resistances are widely spread in the aforementioned group of bacteria.
• the aforementioned bacteria are often resistant to carbapenem, methicillin, vancomycin and fluoroquinolone.
• the bacteriophage according to the present invention can be used as a potent replacement for or supplement to established antibiotic therapy for the treatment of several infectious diseases caused by the aforementioned bacteria, for example furunculosis, osteomyelitis, infections of connective tissue and lymphatic vessels, fistulas, meningitis, septicemia, otitis media, peritonitis, pyogenic arthritis and myositis, osteitis, pyogenic infections of burns, wound infections and mastitis.
• infectious diseases caused by the aforementioned bacteria for example furunculosis, osteomyelitis, infections of connective tissue and lymphatic vessels, fistulas, meningitis, septicemia, otitis media, peritonitis, pyogenic arthritis and myositis, osteitis, pyogenic infections of burns, wound infections and mastitis.
• the use of the bacteriophage according to the present invention in the treatment of bacterial infections is linked with only a low risk of undesired side effects.
• the application of the bacteriophage according to the present invention in the treatment of bacterial infections does not lead to the typical side effects of antibiotics, for example allergic reactions or gastrointestinal complaints as a result of the unspecific effect mechanism.
• a convenient administration of a drug containing the bacteriophage is possible, in particular an intravenous application.
• an application per os is suitable as well as a topical application, for example in the treatment of bladder infections.
• the Caucasian Origin's Bacteriophage has the ability to widely spread through the body when applied systemically, preferably intravenously.
• the phage is able to pass through the blood-brain barrier and is therefore a potent medical substance for the treatment of infections of the brain, particularly meningitis or encephalitis.
• the phages according to the present invention are not only superior with respect to their distribution in the body but also with respect to the kinetics.
• bacteriophages are self-amplifying or self-replicating in the presence of the host, i.e. the pathogenic bacteria to be treated.
• the present invention provides a highly efficient alternative to common antibiotic therapy for the treatment of bacterial infections.
• the use of the bacteriophage in the treatment of bacterial infection addresses the problem of the increasing number of antibiotic resistant bacteria.
• bacteria synonymously also called phage or bacterial virus
• Bacteriophages are composed of proteins that encapsulate a DNA or an RNA genome.
• the bacteriophage according to the present invention has a linear dsDNA genome. Phages usually replicate within the bacterium following the injections of their genome into its cytoplasm. After infection of the bacterial host cell, bacteriophages enter either a lysogenic or lytic lifecycle.
• the lytic lifecycle is of particular relevance.
• the phage attaches to the host cell and injects the phage genome.
• the phage DNA or RNA circularizes and enters either the lytic or lysogenic cycle.
• the host cell's DNA is degraded and the cell's metabolism is directed to initiate phage bio synthesis.
• the phage DNA or RNA is replicated inside the cell, which leads to the expression of new phage DNA and RNA as well as phage proteins. During subsequent maturation, the replicated material assembles to new bacteriophages.
• the newly formed and infectious phages are released from the infected cell.
• the new phages are capable of infecting further host cells.
• the host cell is destroyed and inactivated.
• the crude lysate is purified and/or filtered to remove cell parts of the lysed bacteria and further undesired bacterial substances, for example toxins.
• sterile filtration and/or a concentration of the phage solution can be performed.
• the therapeutic concept of the present invention i.e. the bacteriophage-based therapy of bacterial infection, is - without being bound to this theory - based on the lytic activity of the phages. In other words, the pathogenic bacteria will be destroyed and inactivated through the phage-initiated cell lysis.
• the lytic activity of the Caucasian Origin's Bacteriophage reference is made to the experimental section of this application.
• the bacteriophage of the present invention has a large spectrum of host organisms, particularly bacterial strains belonging to the genera Staphylococcus, Escherichia, Pseudomonas, Klebsiella, Acinetobacter, Proteus, Enterobacter, Enterococcus, Streptococcus and/or Salmonella.
• the bacteriophage is capable of producing a lytic infection in bacteria of the genera Staphylococcus, Escherichia, Enterococcus, Pseudomonas, Klebsiella, Acinetobacter, Proteus, Enterobacter, Streptococcus and/or Salmonella.
• Staphylococcus in the sense of the present invention means a genus of Gram-positive bacteria.
• the genera Staphylococcus includes about 40 species, wherein most of them are harmless for humans and which reside normally on the skin and the mucus membranes of humans and other organisms. Nevertheless, there are some species of Staphylococcus which can lead to severe and even life-threatening bacterial infections.
• Staphylococcus aureus is of particular relevance. Staphylococcus aureus is frequently found in the upper respiratory tract and on the skin. Usually, this species acts as a commensal of the human microbiota without leading to any symptoms. Nevertheless, in particular for people with a weakened immune system or immunocompromised patients, Staphylococcus can become a pathogen, leading to severe skin infections, respiratory infections and food poisoning. In the worst case, infections with Staphylococcus aureus can lead to life-threatening diseases, such as pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, bacteremia and sepsis.
• the bacteriophage according to the present invention is capable of infecting and/or lysing, particularly bacteria of the species Staphylococcus aureus. This applies to cells which are sensitive to antibiotics as well as to antibiotic-resistant strains.
• Escherichia means in the sense of the present invention a genus of Gram-negative rod-shaped bacteria from the family Enterobacteriaceae. Many species of the genus Escherichia are inhabitants of the gastrointestinal tract of animals, in particular also of humans. Even though many Escherichia species are harmless for humans, there exists still a number of pathogenic species. Particularly, several strains of the species Escherichia coli can be harmful to humans. This applies particularly to humans with a deficient or weakened immune system and/or chronic diseases. Pathogenic varieties of Escherichia coli can lead for example to food poisoning, septic shock, meningitis or urinary tract infections.
• strains of Escherichia coli have become resistant against several antibiotics.
• the bacteriophage according to the present invention is capable of infecting bacteria of the genus Escherichia, in particular Escherichia coli, irrespective of the presence of antibiotic resistances of the cells.
• Pseudomonas means in the sense of the present invention a genus belonging to the class of Gammaproteobacteria. Most of the Pseudomonas species are harmless for humans. Nevertheless, the species Pseudomonas aeruginosa is an opportunistic human pathogen. Pseudomonas aeruginosa can for example infect the airway, the urinary tract, burns and wounds and can cause blood infections. With respect to the clinical picture, infections with Pseudomonas aeruginosa can lead to pneumonia, septic shock, urinary tract infections, gastrointestinal infections as well as skin and soft-tissue infections.
• Pseudomonas aeruginosa Particularly vulnerable for infections with Pseudomonas aeruginosa are patients with a weakened immune system, elderly people and people with chronic diseases. Additionally, an increasing number of antibiotic resistant strains of Pseudomonas aeruginosa makes the treatment of infections difficult.
• Klebsiella is understood as a genus of rod-shaped bacteria with a polysaccharide-based capsule. Bacteria of the genus Klebsiella relate to the class of Gammaproteobacteria. With respect to humans, species of Klebsiella often build part of the normal flora of the human nose, mouth and gastrointestinal tract. Nevertheless, some species of Klebsiella can behave as opportunistic human pathogens and lead to several diseases, in particular pneumonia, urinary tract infections, sepsis, meningitis, diarrhea, peritonitis and soft-tissue infections. Most of the infections with Klebsiella species, which require immediate treatment, are caused by the species Klebsiella pneunomiae. Many species of Klebsiella, in particular Klebsiella pneumoniae, have become resistant to a variety of antibiotics, which further complicates the treatment of infections with Klebsiella species, in particular infections with Klebsiella pneumoniae.
• Acinetobacter in context with the present invention means a genus of Gram-negative bacteria, which also belong to the class of Gammaproteobacteria. Usually, species of Acinetobacter are harmless for young or middle-aged and healthy humans. Nevertheless, Acinetobacter species can behave pathogenic in particular in patients with a weakened immune system and are a key source of infections of debilitated patients in hospitals. In this context, the species Acinetobacter baumannii is of particular relevance. Infections with Acinetobacter baumannii can lead to different diseases with a variety of symptoms, for example pneumonia, blood infections, meningitis, wound infections and urinary tract infections.
• species of Acinetobacter in particular Acinetobacter baumannii, have become resistant to several antibiotics, in particular against carbapenem.
• the bacteriophage according to the present invention is capable to infect and lyse cells of Acinetobacter baumannii and Acinetobacter baumannii carbapenem resistant.
• Proteus in connection with the present invention describes a genus of Gram-negative Proteobacteria.
• Proteus species are widely distributed and can be found for example in the human intestine as well as human feces. Most of the Proteus species are harmless for healthy humans. However, in patients with a weakened immune system or elderly people species of Proteus can behave pathogenic and lead for example to blood infections and infections of the urinary tract.
• the species Proteus vulgaris and Proteus mirabilis are opportunistic human pathogens, which particularly lead to urinary tract infections and blood infections.
• the bacteriophage according to the present invention is capable of infecting and/or lysing Proteus species, in particular Proteus vulgaris as well as Proteus mirabilis.
• Enterobacter relates in connection with the present invention to a genus of Gram-negative bacteria of the family Enterobacteriaceae. Many strains of Enterobacter species are pathogenic and cause opportunistic infections in humans with a weakened immune system or chronic diseases. Species of Enterobacter often infect the urinary and respiratory tract. Furthermore, the development of resistances against several antibiotics makes the treatment of patients with infections with Enterobacter species complicated. Many strains of Enterobacter species have become resistant to carbapenem, which is usually the antibiotic of choice for the treatment of Enterobacter infections.
• the bacteriophage of the present invention is capable of infecting and/or lysing species of Enterobacter, in particular carbapenem-resistant Enterobacter species.
• Streptococcus in the sense of the present invention means a genus of Gram-positive spherical bacteria. Species belonging to the genus of Streptococcus can lead to a variety of bacterial infections and/or infectious diseases particularly in humans. Some species of Streptococcus can even have hemolytic properties. Medically relevant Streptococci particularly include Streptococcus pyogenes, which causes pharyngitis, cellulitis and erysipelas, Streptococcus mitis, which causes endocarditis, Streptococcus mutans, which causes dental caries, and Streptococcus pneumoniae, which causes pneumonia. The bacteriophage of the present invention is capable of infecting bacteria of the genus Streptococcus, particularly Streptococcus pyogenes.
• Salmonella in the sense of the present invention means a genus of rod-shaped Gram-negative bacteria belonging to the family Enterobacteriaceae. Salmonella species are facultative intracellular pathogens and can invade several cell types, for example epithelial cells, macrophages, dendritic cells and M cells. Most of the infections with Salmonella are caused by strains of the species Salmonella enterica. The most common path of infection is food, which is infected with Salmonella enterica, particularly cattle and poultry as well as raw eggs. Infections with Salmonella species, in particular Salmonella enterica or Salmonella typhimurium (syn: Salmonella enterica spp. enterica ser.
• the bacteriophage of the present invention is capable of infecting bacteria of the genus Salmonella, particularly Salmonella enterica and/or Salmonella typhimurium.
• the bacteriophage of the present invention has a broad host spectrum and is therefore highly efficient in the treatment of infections with the above described bacteria.
• the bacteriophage is capable to produce lytic infection in several so-called ESKAPE organisms.
• ESKAPE organisms often lead in weakened and hospitalized patients with chronic diseases to severe to life-threatening infections.
• ESKAPE organisms are commonly associated with antimicrobial resistances, particularly against penicillin, methicillin, vancomycin and carbapenems.
• the phage is linked with a high pharmaceutical efficacy in the treatment of such infections as the phage also infects antibiotic resistant bacteria of the aforementioned genera in species. This is quite surprising as most of the phages have a limited specificity, which is particularly limited to a single strain.
• phage has lytic activity and/or antimicrobial activity at least against Escherichia coli, Salmonella enterica, Streptococcus pyogenes, Klebsiella pneumoniae, Proteus vulgaris, Pseudomonas aeruginosa, Acinetobacter baumannii and Staphylococcus aureus.
• the bacteriophage is capable of infecting, especially capable of producing a lytic infection in bacteria with antibiotic resistances, in particular single or multiple antibiotic resistances.
• the bacteriophage according to a further preferred embodiment of the present invention is capable of infecting, especially capable of producing a lytic infection in bacteria with resistances against ⁇ -lactam antibiotics, glycopeptide antibiotics, quinolone antibiotics, polyketide antibiotics, aminoglycoside antibiotics, polypeptide antibiotics and/or sulfonamide antibiotics, in particular methicillin, vancomycin, carbapenem and/or fluoroquinolone.
• the bacteriophage is capable of infecting, especially capable of producing a lytic infection in Klebsiella pneumoniae, Pseudomonas aeruginosa carbapenem-resistant, Pseudomonas aeruginosa, Escherichia coli, Enterobacter spp., Enterobacteriaceae carbapenem-resistant, Enterococcus faecium, Acinetobacter baumannii carbapenem-resistant, Salmonella typhimurium, Salmonella enterica, Proteus vulgaris, Proteus mirabilis, Staphylococcus aureus, Staphylococcus aureus methicillin-resistant, Staphylococcus aureus vancomycin-intermediate, Staphylococcus aureus vancomycin-resistant and/or Streptococcus pyogenes.
• the bacteriophage expresses a nucleic acid sequence, particularly an mRNA sequence, having a nucleotide sequence which has at least 70 %, in particular at least 80 %, preferably at least 85 %, more preferred at least 90 %, further preferred at least 95 %, mostly preferred at least 99 % identity to SEQ. ID. NO. 1.
• the bacteriophage can express a nucleic acid sequence, particularly an mRNA sequence, having a nucleotide sequence which has at least 70 %, in particular at least 80 %, preferably at least 85 %, more preferred at least 90 %, further preferred at least 95 %, mostly preferred at least 99 % identity to SEQ. ID. NO. 2.
• the bacteriophage expresses a nucleic acid sequence, particularly an mRNA sequence, having a nucleotide sequence which has at least 70 %, in particular at least 80 %, preferably at least 85 %, more preferred at least 90 %, further preferred at least 95 %, mostly preferred at least 99 % identity to SEQ. ID. NO. 1 and SEQ. ID. NO. 2.
• the bacteriophage according to the present invention is suitable for the use in the treatment of bacterial infections, in particular bacterial infection caused by bacteria of the genera Staphylococcus, Enterobacter spp., Enterococcus, Escherichia, Pseudomonas, Klebsiella, Acinetobacter, Proteus, Streptococcus and/or Salmonella.
• the bacteriophage can be used in the treatment of infections caused by Klebsiella pneumoniae, Pseudomonas aeruginosa carbapenem-resistant, Pseudomonas aeruginosa, Escherichia coli, Enterobacter spp., Enterobacteriaceae carbapenem-resistant, Enterococcus faecium, Acinetobacter baumannii carbapenem-resistant, Salmonella typhimurium, Salmonella enterica, Proteus vulgaris, Proteus mirabilis, Staphylococcus aureus, Staphylococcus aureus methicillin-resistant, Staphylococcus aureus vancomycin-intermediate, Staphylococcus aureus vancomycin-resistant and/or Streptococcus pyogenes.
• the bacteriophage according to the present invention and/or lysates prepared from that phage are suitable for the use in the treatment of various diseases and symptoms caused by bacterial infections, in particular bacterial infections with the above named bacteria.
• the bacteriophage is suitable for the use in the treatment of furunculosis, osteomyelitis, infections of connective tissue, infections of lymphatic vessels, fistulas, septicemia, meningitis, otitis, peritonitis, arthritis, myositis, osteomyelitis, osteitis, infections of wounds and/or burns, infections of skin and/or mastitis.
• the experimental section shows that the phage has a high therapeutic efficacy in the treatment of bacterial infections with Staphylococcus aureus, Salmonella typhimurium, Salmonella enterica, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Proteus vulgaris, Enterobacter spp., Enterococcus faecium, Pseudomonas aeruginosa, Streptococcus pyogenes and/or Acinetobacter baumannii.
• the present invention provides a highly efficient alternative therapeutic concept for the treatment of bacterial infections.
• the bacteriophage is suitable for the use in the treatment of bacterial infections caused by several different bacterial strains, due to the broad specificity of the phage.
• the bacteriophage as such and/or a treatment on the basis of the bacteriophage address the problem of the increasing number of antibiotic resistant bacteria.
• the present invention relates - according to a second aspect of the present invention - to a pharmaceutical composition for the use in the treatment of bacterial infections and/or infectious diseases, wherein the composition contains a therapeutically effective amount of a bacteriophage, wherein the bacteriophage is a Caucasian Origin's Bacteriophage as deposited at Deutsche Stammsammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under the accession no. DSM 33404.
• DSMZ Deutsche Stammsammlung von Mikroorganismen und Zellkulturen GmbH
• the present invention relates to a pharmaceutical composition, wherein the composition contains the bacteriophage according to the present invention as described above as the pharmaceutically active component.
• the pharmaceutical composition contains a therapeutically effective amount of Caucasian Origin's Bacteriophage, wherein the amount is sufficient to infect bacteria of the genera Staphylococcus, Escherichia, Pseudomonas, Klebsiella, Acinetobacter, Proteus, Enterobacter, Streptococcus and Salmonella.
• the amount of active or infectious bacteriophages in the compositions according to the present invention can vary in wide ranges. Particularly good results in the treatment of bacterial infections are achieved when the composition of the present invention has a phage titer in the range of 1 to 10 15 PFU/ml, especially 10 2 to 10 13 PFU/ml, in particular 10 3 to 10 11 PFU/ml, preferably 10 4 to 10 9 PFU/ml, particularly preferred 10 5 to 10 7 PFU/ml, based on the composition.
• the aforementioned phage titer are therapeutically effective amounts in the sense of the present invention.
• plaque-forming unit is understood according to the present invention as a measure for the number of particles, i.e. bacteriophages, capable of forming plaques per unit volume.
• the number of plaques in a nutrient medium is used for virus quantification and therefore an indicator for the number of infectious virus particles in a defined volume.
• a viral plaque is in this context a visible structure formed within the cell culture, for example bacterial cultures within some nutrient medium. After infecting and penetrating the bacteria, the bacteriophages replicate and spread. Thereby, regions of cell deconstruction are generated. These regions are called plaques. To determine the virus titer, the plaques are counted.
• a PFU of 10 3 means that one milliliter of the composition contains 10 3 bacteriophages, which are capable of infecting bacteria. Additionally, it is indicated that "PFU" is an established term in microbiology and virology. Therefore, no further explanations are necessary for the skilled practitioner with respect to this term.
• the composition comprises the Caucasian Origin's Bacteriophage in the form of a phage lysate.
• the lysate has been obtained from Caucasian Origin's Bacteriophage infected Staphylococcus aureus, Pseudomonas aeruginosa, Proteus vulgaris, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter spp. and/or Staphylococcus pyogenes.
• the composition according to the present invention comprises the bacteriophage on the basis of a combination of lysates, wherein the lysates have been obtained from Caucasian Origin's Bacteriophage infected Staphylococcus aureus, Pseudomonas aeruginosa, Proteus vulgaris, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter spp. and Staphylococcus pyogenes.
• the composition contains the Caucasian Origin's Bacteriophage as the only pharmaceutically active ingredient. Particularly, it is preferred when the composition does not comprise further species of bacteriophages.
• the composition can comprise further pharmaceutically active substances, preferably substances with antimicrobial properties. Such further antimicrobial components can be selected from antibiotics, antiseptics, antimycotics and the like.
• the composition is present as an aqueous composition and/or when the composition is aqueously based and/or is present as an aqueous formulation, especially in the form of an aqueous solution.
• the composition contains water, especially purified water, and/or that the composition contains water as pharmaceutically compatible excipient. Studies performed by applicant have shown that the bacteriophage according to the present invention is particularly stable when diluted in aqueous compositions. Additionally, it is preferred when the composition according to the present invention contains amino acids.
• the amount of water in the composition according to the present invention can vary within wide ranges. According to the invention, it is preferred when the composition has a content of water, especially purified water, of at least 60 % by volume, especially at least 70 % by volume, preferably at least 75 % by volume, particularly preferably at least 80 % by volume, even more preferred at least 88 % by volume, based on the composition.
• compositions according to the present invention when applied to the patients, it is preferred when the composition is present as an isotonic composition, especially solution, in relation to preferably mammalian, in particular human blood and/or blood cells.
• the composition according to the present invention has an osmotic pressure which is identical to the osmotic pressure of mammalian, in particular human blood and or blood cells.
• the composition contains pharmaceutically acceptable, osmotically active substances.
• the composition preferably comprises at least one physiologically safe or acceptable, osmotically active substance and/or at least one physiologically safe or acceptable osmolyte.
• the osmotically active substance and/or osmolyte is selected from the group of ions of physiologically safe or acceptable salts, preferably alkali ions, in particular sodium ions and chloride ions; sugars, in particular glucose; polyols, in particular glycerol; and/or amino acids.
• physiologically safe or acceptable salts preferably alkali ions, in particular sodium ions and chloride ions
• sugars in particular glucose
• polyols in particular glycerol
• amino acids amino acids
• the amount of osmotically active substances in the composition can vary within wide ranges.
• the composition according to the invention contains mono- and/or disaccharides, preferably glucose, in amounts in the range of 0.1 to 25 % by weight, especially 0.5 to 20 % by weight, preferably 1 to 15 % by weight, by preference 2 to 10 % by weight, particularly preferably 3 to 8 % by weight, based on the composition.
• composition according to the invention contains ions of physiologically safe or acceptable salt, in particular sodium ions and chloride ions, in amounts in the range of 0.001 to 5 % by weight, especially 0.01 to 2.5 % by weight, preferably 0.05 to 1.5 % by weight, particularly preferred 0.1 to 1 % by weight, based on the composition.
• physiologically safe or acceptable salt in particular sodium ions and chloride ions
• the composition comprises an amino acid solution. Particularly good results are achieved, when the composition comprises an amino acid solution in amounts in the range of 0.01 to 30 % by volume, especially 0.1 to 25 % by volume, preferably 1 to 20 % by volume, preferred 5 to 15 % by volume, particularly preferred 8 to 12 % by volume, based on the composition.
• the composition comprises at least one customary pharmaceutical additive and/or excipient, which is preferably selected from the group of processing aids, stabilizers, emulsifiers, antioxidants, preservatives, humectants, pH setters, pH buffer substances, thickeners, antiseptics, dyes, buffer substances, odorants, fragrances, extenders, binders, wetting substances and/or preservatives and the combinations thereof.
• the composition comprises a preservative, preferably in a concentration in the range of from 0.0001 to 2 % by weight, especially 0.001 to 1 % by weight, preferably 0.005 to 0.1 % by weight, particularly preferably 0.01 to 0.05 % by weight, based on the composition.
• a preservative is for example quinosole.
• the composition is prepared for an intravenous, subcutaneous, intramuscular, oral, parenteral and/or topical application, especially an intravenous, topical and/or oral application, preferably an intravenous and/or oral application.
• composition according to the present invention can be prepared for any pharmaceutical dosage form. Considering this, the composition can be customized for an optimized dosage form for the respective infection to be treated.
• the bacteriophage according to the present invention has a broad specificity of host cells.
• the compositions according to the present invention containing the respective bacteriophage are suitable for the use in the treatment of several different bacterial infections.
• the pharmaceutical compositions are suitable for the treatment of infections caused by bacteria of the genera Staphylococcus, Enterobacter, Enterococcus, Escherichia, Pseudomonas, Klebsiella, Acinetobacter, Proteus, Streptococcus and/or Salmonella.
• compositions according to the present invention are suitable for the use in the treatment of bacterial infections caused by bacteria selected from Klebsiella pneumoniae, Pseudomonas aeruginosa carbapenem-resistant, Pseudomonas aeruginosa, Escherichia coli, Enterobacter spp., Enterobacteriaceae carbapenem-resistant, Enterococcus faecium, Acinetobacter baumannii carbapenem-resistant, Salmonella typhimurium, Salmonella enterica, Proteus vulgaris, Proteus mirabilis, Staphylococcus aureus, Staphylococcus aureus methicillin-resistant, Staphylococcus aureus vancomycin-intermediate, Staphylococcus aureus vancomycin-resistant and/or Streptococcus pyogenes.
• bacteria selected from Klebsiella pneumoniae, Pseudomonas aeruginosa carba
• the composition can be used for the treatment of several infectious diseases.
• the pharmaceutical composition according to the present invention is used in the treatment of furunculosis, osteomyelitis, infections of connective tissue, infections of lymphatic vessels, fistulas, septicemia, meningitis, otitis, peritonitis, arthritis, myositis, osteomyelitis, osteitis, infections of wounds and/or burns, infections of skin and/or mastitis.
• the present invention relates - according to a third aspect - to a method of treating bacterial infections, comprising administering to a subject in need thereof a Caucasian Origin's Bacteriophage as deposited at Deutsche Stammsammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) and as described above and/or a composition according to the present invention as described above.
• DSMZ Diagnon und Zellkulturen GmbH
• the bacterial infections are particularly caused by bacteria of the genera Staphylococcus, Enterobacter, Enterococcus, Escherichia, Pseudomonas, Klebsiella, Acinetobacter, Proteus, Streptococcus and/or Salmonella, preferably caused by Klebsiella pneumoniae, Pseudomonas aeruginosa carbapenem-resistant, Pseudomonas aeruginosa, Escherichia coli, Enterobacter spp., Enterococcus faecium, Enterobacteriaceae carbapenem-resistant, Acinetobacter baumannii carbapenem-resistant, Salmonella typhimurium, Salmonella enterica, Proteus vulgaris, Proteus mirabilis, Staphylococcus aureus, Staphylococcus aureus methicillin-resistant, Staphylococcus aureus vancomycin-intermediate, Staphyloc
• the method can be used in the treatment of furunculosis, osteomyelitis, infections of connective tissue, infections of lymphatic vessels, fistulas, septicemia, meningitis, otitis, peritonitis, arthritis, myositis, osteomyelitis, osteitis, infections of wounds and/or burns, infections of skin and/or mastitis.
• the lytic and antimicrobial activity of the Caucasian Origin's Bacteriophage have been analyzed. Furthermore, the bacteriophage according to the present invention has been used for the preparation of pharmaceutical compositions particularly for the use in the treatment of bacterial infections. The compositions have been tested with respect to their efficacy in the treatment of different bacterial infections.
• a Caucasian Origin's BP as deposited at the Deutsche Stammsammlung von Mikroorganismen und Zellkulturen GmbH (DSMZ) under the accession number no. 33404 has been used.
• the bacteriophage was cultivated and isolated.
• the following cultivation media have been used: Special Medium (SM): 5.8 g NaCl 2.0 g MgSO4 ⁇ 7 H 2 O 4.5 ml 1 M Tris HCI pH 7 5.0 ml 2 % gelatin q.s. to 1 liter, sterilize by autoclaving
• LEM 10.0 g Bacto-tryptone 5.0 g Yeast extract 5.0 g NaCl 10.0 ml 1 M MgSO 4 q.s. to 1 liter, sterilize by autoclaving
• LB-Medium 10.0 g Tryptone 5.0 g Yeast extract 10.0 g NaCl q.s. to 1 liter, sterilize by autoclaving
• an overnight culture of the selected bacteriophage's host cell species for example Staphylococcus aureus, Salmonella typhimurium, Salmonella enterica, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Proteus vulgaris, Enterobacter spp., Enterococcus faecium, Pseudomonas aeruginosa, Streptococcus pyogenes or Acinetobacter baumannii
• the overnight culture is further used for inoculation of either a 3 hour culture or another fresh overnight culture.
• a 1 : 10 dilution of the overnight culture is cultivated in LB media for 3 hours at 37 °C.
• the fresh overnight culture or the 3 hour culture are used for phage amplification.
• Phage amplification can be performed by following the general procedure for plating and titering of Lambda stocks.
• the bacteria on which the strain is to be grown are cultured overnight by sterile transfer from a stab or slant to a medium size culture tube containing 5 ml LB with 0.1 M MgSO 4 and, optionally, further additions, for example 1 ⁇ g/ml for thiamine or 5 ⁇ g/ml thymine or thymidine.
• the culture is grown about 14 hours at 37 °C.
• dilute the phage in SM to a final phage concentration of about 2 ⁇ 10 3 PFU/ml. Dilutions are done by adding 0.05 ml to 5 ml of SM for a 102 dilution or by adding 0.5 ml to 4.5 ml SM for a tenfold dilution.
• 0.1 ml of the phage dilution are added to 0.25 ml of the 3 hour culture and preabsorbed at 37 °C for 5 to 10 min.
• 2.5 ml top agarose (melted and tempered at 45 °C to 47 °C) are added to each tube and poured onto bottom agar plates. If thiamine is a requirement, it is added to the top agar. The plates are incubated at 37°C overnight. If the bacterium is temperature sensitive, the preabsorption and overnight incubation is performed at an appropriate temperature.
• the purification of phage infected strains can be performed according to established purification protocols.
• a single, well isolated plaque is selected.
• the plaque is removed from the plate using a sterile open-ended capillary tube or pasteur pipette to pierce the agar (both top and bottom layers).
• the plaque is expelled into 1.0 ml SM plus a drop of chloroform and shaken briefly to suspend the phage.
• One single plaque usually contains an average of 10 5 to 10 6 phages.
• a 10 3 and 10 4 dilution of the suspension is plated out. At least two cycles are carried out.
• a single plaque is cored out and added to 1 ml SM.
• 0.5 ml phage are added to 0.15 ml of a 3 hours culture of appropriate bacteria. Bacteria and phage are incubated for 20 min at 37 °C. 3 ml of top agarose are added. The mixture is plated out on a fresh agar plate. Within approximately 4 hours, bacteria growth is apparent. After 1 to 2 more hours, substantial clearing is apparent. When almost all, but not all, bacteria have been lysed, 3 ml SM are added to the plate. The plate is stored at 4 °C. After 1 hour to overnight, the SM is taken off with a sterile pasteur pipet. The resulting stock of phage has a titer of approximately 5 x 10 9 PFU/ml.
• an overnight culture of the selected bacteriophage's host cell species is grown overnight.
• the bacteria, the phage and cultivation medium are preabsorbed at 37 °C for 10 to 20 min.
• 5 ml bacteria and 2 x 10 7 phages are inoculated.
• 500 ml LEM are pre-warmed at 37 °C in a 2 liter flask.
• the inoculant is added to the media and shaken vigorously at 37 °C until lysis is complete (4 or 5 hours to overnight).
• 4 ml per 500 ml media chloroform and NaCl are added to lyse remaining cells.
• the mixture is shaken for 15 min. at 37 °C and chilled afterwards.
• the mixture is centrifuged for 15 min. with 8.000 rpm. After centrifugation, polyethylene glycol (PEG) 6000 is added to 7 % by weight to the supernatant. The PEG is dissolved by shaking. The mixture is incubated at cold temperatures for at least 1 hour. After incubation, the supernatant is removed by centrifugation for 15 min. with 8.000 rpm. All residual fluid is wiped out and the pellet is resuspended in 7 ml SM. The suspended pellet is transferred to a centrifuge tube. Include the clumps. Crude DNase is added with 20 ⁇ g/ml. The suspension with DNase is incubated for 20 min. at room temperature. Cell debris is removed through centrifugation for 15 min.
• PEG polyethylene glycol
• the solution is cooled and extracted with phenol, wherein a phenol : chloroform ratio of 50 : 50 is used. Afterwards, ether extraction with subsequent ethanol precipitation either by spooling out or spinning down the DNA is performed. After a wash step with ethanol, the DNA is taken up and solved in standard DNA buffer.
• agar plates have been prepared as growth media with three different concentrations of the bacteriophage lysate (0.01 wt.-%, 0.16 wt.-% and 0.23 wt.-%, based on the growth media, of a bacteriophage lysate with a phage titer of 1 x 10 7 PFU/ml phages).
• Each agar plate contained 10 g of growth media.
• agar plates without the addition of bacteriophage have been used.
• Caucasian Origin's Bacteriophage has the ability to inhibit the growth of the tested bacterial strains. It can be summarized that Caucasian Origin's Bacteriophage has lytic properties against a variety of bacteria, in particular Staphylococcus aureus, Acinetobacter baumannii, Pseudomonas aeruginosa and Salmonella enterica.
• agar plates have been prepared with several antibiotics in three different concentrations (Azlocillin, Piperacillin/Tazo, Sultamicillin, Oxacillin, Flucloxacillin, Amoxicillin, Clavulanic acid, Ceftriaxone, Meropem, Cefepime, Cefotaxime, Cefuroxime, Cefoperazone, Vancomycin, Gentamicin, Amikacin, Azithromycin, Roxithromycin, Rovamycine, Clarithromycin, Moxifloxacin, Ofloxacin, Ciprofloxacin, Doxycycline, Rifampin, Linomycin, Imipenem/Cilastin).
• the concentrations for each antibiotic were individually adapted to the respective substance.
• the concentrations for each antibiotic (unit: mg/L) are indicated in the table below.
• agar plates containing three different concentrations of Caucasian Origin's Bacteriophage have been prepared.
• the solid growth media (agar plates) contained 0.9 wt.-%, 1.6 wt.-% and 2.3 wt.-% of a phage stock/lysate with a phage titer of 1 x 10 7 PFU/ml.
• Bacteria of the aforementioned species have been plated out on the agar plates and incubated for 3 days.
• agar plates without antibiotics and without bacteriophage have been used.
• the tested bacterial strains are resistant to several of the tested antibiotics.
• Caucasian Origin's Bacteriophage is capable to inhibit the growth of the tested bacterial strains.
• a phage fluid lysate with a titer of 1 x 10 7 PFU/ml has been prepared.
• 0.2 ⁇ l of the bacteriophage solution or lysate have been added to the bacterial cultures.
• Bacteria cultures and bacteriophage were incubated for 3 days. The number of lysed pathogen isolates were counted.
• the latent period in minutes was analyzed as well as the productivity of the infection (PFU/cell or phage yield per cell). The respective results are contained in Table 3 below.
• Table 3 Lysis studies Number of lysed pathogen isolates Latent period in minutes Productivity [PFU/cell] Host Bacteria 48 (50) 45 170 Staphylococcus aureus 44 (50) 49 110 Pseudomonas aeruginosa 42 (50) 57 60 Proteus vulgaris 46 (50) 60 110 Escherichia coli 37 (50) 55 150 Acinetobacter baumannii 43 (50) 47 120 Klebsiella pneumoniae 45 (50) 35 70 Enterobacter spp. 44 (50) 33 47 Streptococcus pyogenes
• Caucasian Origin's Bacteriophage is highly capable of lysing bacteria belonging to the species Staphylococcus aureus, Pseudomonas aeruginosa, Proteus vulgaris, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter spp. and Staphylococcus pyogenes. Additionally, the phage has a relatively short latent period when infecting the aforementioned bacteria. The short latent period is advantageous with respect to the therapeutical use of Caucasian Origin's Bacteriophage in the treatment of infections with the above mentioned bacteria.
• a phage stock / phage lysate has been prepared according to the above described protocols.
• a composition for intravenous application according to Table 4 has been prepared.
• a second pharmaceutical composition for use in the treatment of bacterial infections has been prepared on the basis of Caucasian Origin's Bacteriophage lysates generated from eight strains of host bacteria ( Staphylococcus aureus, Pseudomonas aeruginosa, Proteus vulgaris, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter spp. and Staphylococcus pyogenes ). The host bacteria had been isolated from 50 patients suffering from bacterial sepsis (cf. lysis studies).
• lysates of Caucasian Origin's Bacteriophage have been prepared according to the preparation protocols as described above.
• the host strains were Staphylococcus aureus, Pseudomonas aeruginosa, Proteus vulgaris, Escherichia coli, Acinetobacter baumannii, Klebsiella pneumoniae, Enterobacter spp. and Staphylococcus pyogenes.
• the eight lysates were combined. Bacterial cell parts and undesired residues were removed. A sterilization filtration was performed.
• the phage titer of the combined lysate composition was 1 x 10 7 PFU/ml. Additionally, 0.01 % by weight, based on the composition, of quinosole as a preservative have been added.
• the composition has been used in a clinical trial on 50 patients suffering from acute bacterial sepsis.
• first and second efficacy study the efficacy of the above described first pharmaceutical compositions as a pathogen-specific therapy for bacterial infections caused by staphylococci and several gram-negative bacteria (Staphylococcus aureus, Staphylococcus aureus methicillin-resistant, Staphylococcus aureus vancomycin-intermediate/resistant, Acinetobacter baumannii carbapenem-resistant, Klebsiella pneumoniae, Escherichia coli, Enterobacter spp., Proteus mirabilis, Proteus vulgaris, Proteus faecium, Salmonella typhimurium, Salmonella enterica and Pseudomonas aeruginosa carbapenem-resistant) has been evaluated.
• the patients received intravenously a daily dose of the composition of 15 to 20 ml per kg bodyweight.
• a daily dose of the composition of 15 to 20 ml per kg bodyweight.
• an initial loading dose of 25 ml per kg bodyweight was applied.
• a daily dose of 1.5 to 20 ml/kg was applied.
• the infections have been analyzed with respect to their bacterial colonization.
• bacteria have been isolated from the infection.
• the bacteria have been further analyzed by using microbiological standard techniques, in particular RT-PCR, PCR, fluorescent spectrophotometers as well as microscopy (fluorescent microscope, inverted microscope, video microscope).
• suppurative bacterial infections caused by staphylococci and Gram-negative bacteria Acinetobacter baumannii carbapenem-resistant, Klebsiella, Escherichia, Proteus and Pseudomonas aeruginosa carbapenem-resistant
• Positive therapeutic effects were obtained in 168 cases, i.e. 65.625 %. It was found that bacteriophage therapy effectively controls the infections process irrespective of its localization, patient age and sex, and type of infection (mono-infections, poly-infections).
• the highest effectiveness of the bacteriophage therapy was noted in furunculosis (100 % of the treated patients cured). High effectiveness (over 90 % of the treated patients cured) was also observed in osteomyelitis, infections of connective tissue and lymphatic vessels, as well as chronic suppurative fistulas and in oncological patients with High CRP level. Overall, the use of the bacteriophage according to the present invention for therapy of bacterial infections revealed very positive results, where antibiotics were ineffective.
• bacteriophage therapy was highly effective in the treatment of infections caused by different species of bacteria, as Escherichia, Klebsiella, Proteus, Enterobacter, Pseudomonas and Staphylococcus aureus (furunculosis).
• bacteriophage therapy was most effective in purulent meningitis, Acinetobacter baumannii (carbapenem-resistant), Pseudomonas aeruginosa, (carbapenem-resistant), Enterobacteriaceae (carbapenem-resistant), Enterococcus faecium (vancomycin-resistant), Salmonella enterica (fluoroquinolone-resistant), Staphylococcus aureus (methicillin-resistant, vancomycin-intermediate and resistant) and furunculosis (90 to 100 % cured).
• the second pharmaceutical composition was used in a clinical trial for the treatment of 50 patients suffering from acute moderate bacterial sepsis.
• the treatment was successful, i.e. no supplementation of therapy with additional antibiotics was necessary. None of the patients suffered from undesired side effects.
• 82 % of the treated sepsis cases were cured without using antibiotics.
• a treatment without antibiotics is not only advantageous with respect to reduced side effects but also with respect to a containment of the development resistances of antibiotics.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• General Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Genetics & Genomics (AREA)
• Microbiology (AREA)
• Zoology (AREA)
• Pharmacology & Pharmacy (AREA)
• Wood Science & Technology (AREA)
• Animal Behavior & Ethology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Engineering & Computer Science (AREA)
• Virology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Biomedical Technology (AREA)
• Biotechnology (AREA)
• Communicable Diseases (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Immunology (AREA)
• General Chemical & Material Sciences (AREA)
• Biochemistry (AREA)
• General Engineering & Computer Science (AREA)
• Mycology (AREA)
• Epidemiology (AREA)
• Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Applications Claiming Priority (1)

Publications (1)

Family

ID=70108030

Family Applications (1)

Country Status (1)

Cited By (1)

Citations (2)

• 2021
  • 2021-03-19 EP EP21163701.2A patent/EP3928782A1/fr active Pending

Patent Citations (2)

Non-Patent Citations (2)

Similar Documents

Legal Events